TREM2-independent neuroprotection is mediated by monocyte-derived macrophages in a mouse model of Alzheimer's disease.

Overall, our findings highlight a novel TREM2-independent pathway by which cognitive improvement and removal of soluble-Aβ are achieved in an amyloidosis model. Thus, our results support the potential of MDM-harnessing immunotherapy in treating AD patients, irrespective of whether they carry a TREM2 mutation.